Molecular diagnosis has become one of the important solutions in the field of tumor diagnosis and treatment. From early screening and diagnosis tools for high-risk and healthy populations, to molecular typing of tumors, precise medication guidance for advanced tumor patients, and detection of tiny residual lesions in tumor patients to assess recurrence risk, the clinical application value of molecular diagnosis is gradually penetrating into the intervention and management of the entire tumor life cycle.
In recent years, the molecular diagnosis industry has shown good development trends in terms of technological development, policy support, market demand, and industrial cooperation. Molecular diagnostic companies are applying their research and development achievements to practical diagnosis and treatment, continuously gathering strength in technology research and development, product quality, service levels, etc., to promote the emergence of higher-quality molecular diagnostic products that better meet clinical precision needs and benefit the public.
Against this backdrop, Frost & Sullivan (Frost & Sullivan, abbreviated as 'Frost & Sullivan') will release the 'Blue Book on the Development of the Tumor Molecular Diagnosis Industry'. This 'Blue Book' analyzes the current situation of the tumor molecular diagnosis industry, tracks the cutting-edge trends in industry and technology development, and examines the driving factors behind market development.
